Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

Donat Dürr; Raffaele Daniele Siciliano; Yvonne Hummel; Alix O’Meara; Anita Hirschi; Roger Burkhard; Hanspeter Honegger

首页> 外文期刊>Annals of Hematology >Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

【24h】

Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

机译：来那度胺5q减去骨髓增生异常综合症：多长时间足够？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of Hematology》 |2010年第1期|p.105-106|共2页
作者
Donat Dürr; Raffaele Daniele Siciliano; Yvonne Hummel; Alix O’Meara; Anita Hirschi; Roger Burkhard; Hanspeter Honegger;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough? [J] . Donat Diirr, Raffaele Daniele Siciliano, Yvonne Hummel, Annals of hematology . 2010,第1期

机译：来那度胺5q减去骨髓增生异常综合症：多长时间足够？
2. Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health [J] . List Alan F., Sun Zhuoxin, Verma Amit, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：来那度胺（LEN）和依泊汀阿尔法（EA）联合治疗在难治性促红细胞生成素（Epo），低风险（LR）5q [Del（5q）]骨髓增生异常综合征（MDS）患者中优于单独的来那度胺E2905组间研究（ECOG-ACRIN癌症研究组研究），格兰特CA180820，以及美国国立卫生研究院国立癌症研究所
3. Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes [J] . Giagounidis Aristoteles A. N. Seminars in Hematology . 2012,第4期

机译：来那度胺用于del（5q）和non-del（5q）骨髓增生异常综合症
4. LncRNAs and Protein-coding Genes Expression Analysis for Myelodysplastic Syndromes Diagnoses [C] . Lama Al-Bakhat, Norah Al-Serhani International Conference on Artificial Intelligence Modern Assistive Technology . 2020

机译：髓细胞增强综合征诊断的LNCRNA和蛋白质编码基因表达分析
5. Chronic Bone Marrow Failure and Transfusion Patterns: Epidemiological Studies of Blood Transfusions and Outcomes in Patients with Myelodysplastic Syndromes [D] . Rydén, Jenny. 2021

机译：慢性骨髓衰竭和输血模式：骨髓增生综合征患者出血和结果的流行病学研究
6. Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes [O] . Leylah M. Drusbosky, Christopher R. Cogle 2020

机译：非Del（5q）骨髓增生异常综合征中来那度胺敏感性和耐药机制的鉴定
7. Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough? [O] . Donat Dürr, Raffaele Daniele Siciliano, Yvonne Hummel, 2009

机译：Lenalidomide 5季度，5季度myelodysplastic综合征：足够长吗？
8. Role of mDia1 in the Aberrant Innate Immune Signaling in del(5q) Myelodysplastic Syndromes. [R] . Ji, P. 2017

机译：mDia1在del（5q）骨髓增生异常综合征中的异常先天免疫信号中的作用。

Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

著录项

相似文献

相关主题

期刊订阅